https://www.onclive.com/onclive-tv/dr-jonasch-on-sequencing-challenges-in-rcc
Dr. Jonasch on Sequencing Challenges in RCC

Eric Jonasch, MD



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses sequencing challenges facing patients with renal cell carcinoma (RCC).

A sequencing challenge in the second-line setting is whether to start with a checkpoint antibody, such as nivolumab (Opdivo) or a multikianse inhibitor like cabozantinib (Cabometyx).

Nivolumab is well tolerated for the majority of patients who receive it. There is a subset of individuals who benefit from it. At this point in time, there are not good predictors of which agent should be given to which patient.
 
Printer Printing...